Single Intravenous Bolus versus Continuous Infusion of Tranexamic Acid to Reduce Blood Loss in Transurethral Resection of Prostate: a Prospective Randomized Double-Blind Study

Abstract

Benign Prostatic Hyperplasia (BPH) has become a significant public health problem adding to the cost of health care in the society. Transurethral resection of the prostate (TURP) remains the gold standard treatment of BPH. Perioperative morbidity from this procedure ranges between 18% and 26% and the mortality rate may be as high as 1%. Though the mortality of TURP has decreased to less than 1%, the significant morbidity of the bleeding complications still persists. An ideal complication-free treatment of BPH still remains a mirage. From treatment by medicine using alpha blockers and 5-alpha reductase inhibitors to laser prostatectomies, all treatment modalities have their own side effects.